BNP Paribas Financial Markets
NBSE

BNP Paribas Financial Markets’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

BNP Paribas Financial Markets’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-3
Closed -$2.65K – 3645
2015
Q1 		$2.65K Buy
+3
New +$9.9K ﹤0.01% 3417
2014
Q4 		– Sell
-4
Closed -$10.7K – 3352
2014
Q3 		$10.7K Buy
+4
New +$13.2K ﹤0.01% 3550

Other funds holding NBSE

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TI
Turner Investments Berwyn, Pennsylvania $134K AUM 49.03% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
SIP
Stoneridge Investment Partners Radnor, Pennsylvania $152M AUM 20.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BNP Paribas Financial Markets's NBSE Position: Q2 2015 in Review

BNP Paribas Financial Markets sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2015, closing a stake of 3 shares — an estimated $2.65K sold.

BNP Paribas Financial Markets first reported a position in NBSE in Q3 2014 and held it in 2 quarters. The position peaked at $10.7K in Q3 2014. 66 funds tracked by Wall St. Rank hold NBSE as of Q2 2015.

  • BNP Paribas Financial Markets reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2015 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 3 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2015, an estimated $2.65K.
  • BNP Paribas Financial Markets first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q3 2014 and held it in 2 quarters.
  • BNP Paribas Financial Markets's NeuBase Therapeutics, Inc. Common Stock position peaked at $10.7K in Q3 2014.
  • 66 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2015.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2015, filed 14 Aug 2015.